Gelonghui, March 18 | Yahong Pharmaceutical announced the results of the APL-1702 international multi-center phase III clinical trial of its non-surgical treatment of high-grade cervical squamous intraepithelial lesion (HSIL) products, showing that in terms of main efficacy endpoints, the response rate of the APL-1702 group increased by 89.4% compared to the placebo control group, showing significant curative effects. At the same time, APL-1702 increased clearance of high-risk HPV16 and/or HPV18, and the APL-1702 group increased 103.9% compared to the control group. Both groups had lower rates of TRAE (treatment-related adverse events) and SAE (serious adverse events). APL-1702 is the world's first non-surgical HSIL treatment product with international phase III clinical verification and accurate curative effect. The company expects to submit a new drug marketing application in Q2 this year.